Why the study?
Despite extensive preclinical promise, antioxidant therapies for myocardial ischemia-reperfusion injury have consistently failed in clinical translation.
The review emphasizes that overcoming the translational gap of antioxidant therapies in MIRI requires a shift towards precision medicine.
Answers are grounded in this paper and cite their sources.
Antioxidant strategies should not inform MIRI care; leaves open whether precision approaches can overcome prior translational failures.
Myocardial ischemia-reperfusion injury (MIRI) remains a major clinical challenge, with oxidative stress as a key driver. Despite extensive preclinical promise, antioxidant therapies have consistently failed in clinical translation. This critical review deconstructs this translational gap, which stems from the nuanced complexity of redox biology, inappropriate therapeutic timing, and patient heterogeneity. We argue that overcoming these hurdles requires a paradigm shift from broad antioxidant supplementation to precision medicine. This approach involves enhancing endogenous defense mechanisms, leveraging targeted drug delivery, and developing multi-modal strategies. Ultimately, integrating dynamic biomarkers, multi-omics, and artificial intelligence to tailor treatments to individual patient profiles holds the key to finally fulfilling the promise of effectively managing MIRI.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: